0001492298-20-000043.txt : 20201208 0001492298-20-000043.hdr.sgml : 20201208 20201208090403 ACCESSION NUMBER: 0001492298-20-000043 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20201207 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20201208 DATE AS OF CHANGE: 20201208 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Sabra Health Care REIT, Inc. CENTRAL INDEX KEY: 0001492298 STANDARD INDUSTRIAL CLASSIFICATION: REAL ESTATE INVESTMENT TRUSTS [6798] IRS NUMBER: 272560479 STATE OF INCORPORATION: MD FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34950 FILM NUMBER: 201374489 BUSINESS ADDRESS: STREET 1: 18500 VON KARMAN STREET 2: SUITE 550 CITY: IRVINE STATE: CA ZIP: 92612 BUSINESS PHONE: 888-393-8248 MAIL ADDRESS: STREET 1: 18500 VON KARMAN STREET 2: SUITE 550 CITY: IRVINE STATE: CA ZIP: 92612 8-K 1 sbra-20201207.htm 8-K sbra-20201207
false000149229800014922982020-12-072020-12-07

  
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): December 7, 2020
SABRA HEALTH CARE REIT, INC.
(Exact name of registrant as specified in its charter)
 
Maryland 001-34950 27-2560479
(State of
Incorporation)
 (Commission
File Number)
 (I.R.S. Employer
Identification No.)
 
18500 Von Karman AvenueSuite 550
Irvine
CA
92612
(Address of principal executive offices)(Zip Code)
Registrant's telephone number including area code: (888393-8248  
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:  
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading symbol(s)Name of each exchange on which registered
Common stock, $0.01 par valueSBRAThe Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.



Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Appointment of Director
On and effective as of December 7, 2020, the Board of Directors of Sabra Health Care REIT, Inc., a Maryland corporation (the “Company”), appointed Clifton J. Porter II to serve as a member of the Board of Directors until the Company’s 2021 Annual Meeting of Stockholders and until his successor is duly elected and qualifies.
As a non-employee director, Mr. Porter will receive compensation in the same manner as the Company’s other non-employee directors, in accordance with the Company’s Directors’ Compensation Policy, which is attached as Exhibit 10.9 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the Securities and Exchange Commission on February 24, 2020, which exhibit is incorporated herein by this reference.
There is no arrangement or understanding between Mr. Porter and any other persons pursuant to which Mr. Porter was appointed as a director, and Mr. Porter has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.
Item 9.01Financial Statements and Exhibits
 
(d)Exhibits.
99.1
104Cover Page Interactive Data File (embedded within the Inline XBRL document).





SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
SABRA HEALTH CARE REIT, INC.
/S/    HAROLD W. ANDREWS, JR.
Name: Harold W. Andrews, Jr.
Title: Executive Vice President, Chief Financial
Officer and Secretary
Dated: December 8, 2020




EX-99.1 2 cliftonporterpressrele.htm EX-99.1 Document

Sabra Health Care REIT Appoints Clifton J. Porter II to Board of Directors

IRVINE, Calif.--(BUSINESS WIRE)-- Sabra Health Care REIT, Inc. (“Sabra”) (Nasdaq: SBRA) today announced the appointment of Clifton J. Porter II to its Board of Directors.
Clifton J. Porter II currently serves as Senior Vice President of the American Healthcare Association/ National Center for Assisted Living and is responsible for leading and executing the Association’s policy and legislative agenda impacting both the skilled nursing and assisted living sectors. Mr. Porter has over 31 years of experience in the long-term care profession, starting in operations as an Administrator in Training in 1989 ultimately leading to the oversight of multiple facilities in a large urban market. In 2004, Mr. Porter developed and led the Government Relations function for one of the largest post-acute companies in the country and covered both state and federal policy/legislative oversight. In 2013 Mr. Porter assumed his current duties at AHCA/NCAL.
Mr. Porter possesses the understanding and experience of an operator and has the unique ability to overlay policy implications through a real-world lens. He has been intricately involved in landmark legislation including the IMPACT Act, Physician SGR repeal, SNF Value Based Purchasing, Medicaid reform legislation and most recently the government’s response to the COVID pandemic.
Mr. Porter is a 1989 graduate of the Medical College of Virginia, Virginia Commonwealth University with a BS in Healthcare Management. He also serves in varying volunteer endeavors focused on the leadership development of African-American college students.
Commenting on Mr. Porter’s appointment to the Board, Rick Matros, CEO and Chairman, said, “I have known Clif for over thirty years. His expertise in the policy arena and his relationships on Capitol Hill are unique to the Sabra Board and invaluable as we continue to grow the company’s existing asset classes. As important, his professionalism, integrity and the transparency with which he operates fits perfectly with the culture of the Sabra Board and Sabra as a company. Joining the Board now as we navigate through COVID and move forward into the post COVID world is particularly timely and important.”
About Sabra
Sabra operates as a self-administered, self-managed real estate investment trust (a “REIT”) that, through its subsidiaries, owns and invests in real estate serving the healthcare industry throughout the United States and Canada.
Investor & Media Inquiries: 1-888-393-8248 or investorinquiries@sabrahealth.com


EX-101.SCH 3 sbra-20201207.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 4 sbra-20201207_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 5 sbra-20201207_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 6 sbra-20201207_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Written Communications Written Communications Pre-commencement Tender Offer Pre-commencement Tender Offer Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, City or Town Entity Address, City or Town Soliciting Material Soliciting Material Entity Address, Address Line One Entity Address, Address Line One Security Exchange Name Security Exchange Name Entity Address, Address Line Two Entity Address, Address Line Two City Area Code City Area Code Cover [Abstract] Cover [Abstract] Entity Tax Identification Number Entity Tax Identification Number Entity File Number Entity File Number Entity Central Index Key Entity Central Index Key Document Type Document Type Entity Emerging Growth Company Entity Emerging Growth Company Title of 12(b) Security Title of 12(b) Security Local Phone Number Local Phone Number Entity Address, State or Province Entity Address, State or Province Amendment Flag Amendment Flag Entity Address, Postal Zip Code Entity Address, Postal Zip Code Trading Symbol Trading Symbol Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name EX-101.PRE 7 sbra-20201207_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 8 sbra-20201207_htm.xml IDEA: XBRL DOCUMENT 0001492298 2020-12-07 2020-12-07 false 0001492298 8-K 2020-12-07 SABRA HEALTH CARE REIT, INC. MD 001-34950 27-2560479 18500 Von Karman Avenue Suite 550 Irvine CA 92612 888 393-8248 false false false false Common stock, $0.01 par value SBRA NASDAQ false XML 9 R1.htm IDEA: XBRL DOCUMENT v3.20.2
Document and Entity Information
Dec. 07, 2020
Cover [Abstract]  
Title of 12(b) Security Common stock, $0.01 par value
Document Type 8-K
Amendment Flag false
Document Period End Date Dec. 07, 2020
Entity Registrant Name SABRA HEALTH CARE REIT, INC.
Entity Central Index Key 0001492298
Entity Incorporation, State or Country Code MD
Entity File Number 001-34950
Entity Tax Identification Number 27-2560479
Entity Address, Address Line One 18500 Von Karman Avenue
Entity Address, Address Line Two Suite 550
Entity Address, City or Town Irvine
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92612
City Area Code 888
Local Phone Number 393-8248
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Trading Symbol SBRA
Security Exchange Name NASDAQ
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 1 95 1 false 0 0 false 0 false false R1.htm 0001001 - Document - Document and Entity Information Sheet http://www.sabrahealth.com/role/DocumentandEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports sbra-20201207.htm cliftonporterpressrele.htm sbra-20201207.xsd sbra-20201207_cal.xml sbra-20201207_def.xml sbra-20201207_lab.xml sbra-20201207_pre.xml http://xbrl.sec.gov/dei/2019-01-31 true true JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "sbra-20201207.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "calculationLink": { "local": [ "sbra-20201207_cal.xml" ] }, "definitionLink": { "local": [ "sbra-20201207_def.xml" ] }, "inline": { "local": [ "sbra-20201207.htm" ] }, "labelLink": { "local": [ "sbra-20201207_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "sbra-20201207_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "sbra-20201207.xsd" ], "remote": [ "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "sbra", "nsuri": "http://www.sabrahealth.com/20201207", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "sbra-20201207.htm", "contextRef": "i7a715c7bf29046d39462779d64a15d2b_D20201207-20201207", "decimals": null, "first": true, "lang": "en-US", "name": "dei:Security12bTitle", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Document and Entity Information", "role": "http://www.sabrahealth.com/role/DocumentandEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "sbra-20201207.htm", "contextRef": "i7a715c7bf29046d39462779d64a15d2b_D20201207-20201207", "decimals": null, "first": true, "lang": "en-US", "name": "dei:Security12bTitle", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.sabrahealth.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.sabrahealth.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.sabrahealth.com/role/DocumentandEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.sabrahealth.com/role/DocumentandEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.sabrahealth.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.sabrahealth.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.sabrahealth.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.sabrahealth.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.sabrahealth.com/role/DocumentandEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.sabrahealth.com/role/DocumentandEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.sabrahealth.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.sabrahealth.com/role/DocumentandEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.sabrahealth.com/role/DocumentandEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.sabrahealth.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.sabrahealth.com/role/DocumentandEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.sabrahealth.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.sabrahealth.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.sabrahealth.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.sabrahealth.com/role/DocumentandEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.sabrahealth.com/role/DocumentandEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.sabrahealth.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.sabrahealth.com/role/DocumentandEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.sabrahealth.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 16 0001492298-20-000043-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001492298-20-000043-xbrl.zip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end